588 (Previous rank: 615)
FRX
|
|
Howard Soloman
909 Third Ave., New York, NY 10022
212-421-7850
http://www.frx.com
|
| Revenues |
3,159.6 |
17.9 |
| Profits |
838.8 |
14 |
| Assets |
3,705.0 |
— |
| Stockholders' Equity |
3,132.4 |
— |
| Market Value 3/17/2006 |
14,570.5 |
— |
| Revenues |
26.5 |
| Assets |
22.6 |
| Stockholders' equity |
26.8 |
|
| 2005 $ |
2.25 |
| % change from 2004 |
15.4 |
| 1995-2005 annual growth rate % |
23.7 |
|
| 2005 |
-9.3 |
| 1995-2005 annual rate |
21.8 |
| Industry: Pharmaceuticals |
| 1 |
Pfizer
|
31 |
51,353.0 |
| 2 |
Johnson & Johnson
|
32 |
50,514.0 |
| 3 |
Abbott Laboratories
|
93 |
22,337.8 |
| 4 |
Merck
|
95 |
22,011.9 |
| 5 |
Bristol-Myers Squibb
|
110 |
20,222.0 |
| 6 |
Wyeth
|
119 |
18,755.8 |
| 7 |
Eli Lilly
|
148 |
14,645.3 |
| 8 |
Amgen
|
181 |
12,430.0 |
| 9 |
Schering-Plough
|
250 |
9,508.0 |
| 10 |
Forest Laboratories
|
588 |
3,159.6 |
| 11 |
Genzyme
|
643 |
2,734.8 |
| 12 |
Hospira
|
660 |
2,626.7 |
| 13 |
Biogen Idec
|
706 |
2,422.5 |
| 14 |
Allergan
|
734 |
2,319.2 |
| 15 |
Gilead Sciences
|
801 |
2,028.4 |
| 16 |
Chiron
|
828 |
1,919.7 |
| 17 |
King Pharmaceuticals
|
865 |
1,774.7 |
| 18 |
NBTY
|
880 |
1,737.2 |
| 19 |
Watson Pharmaceuticals
|
917 |
1,646.2 |
From the April 17th, 2006 issue
|
| Most profitable companies |
| Women CEOs of FORTUNE 500 companies |
 There are more women running FORTUNE 500 companies this year than there were last year. Currently, 10 FORTUNE 500 companies are run by women (up from 9 last year), and a total of 20 FORTUNE 1000 companies have women in the top job (up from 19). (more) |
|
